Oncotarget

Research Papers:

Differentiation between genetic mutations of breast cancer by breath volatolomics

Orna Barash, Wei Zhang, Jeffrey M. Halpern, Qing-Ling Hua, Yue-Yin Pan, Haneen Kayal, Kayan Khoury, Hu Liu, Michael P.A. Davies and Hossam Haick _

PDF  |  HTML  |  Supplementary Files  |  How to cite  |  Order a Reprint

Oncotarget. 2015; 6:44864-44876. https://doi.org/10.18632/oncotarget.6269

Metrics: PDF 806 views  |   HTML 1626 views  |   ?  


Abstract

Orna Barash1,*, Wei Zhang2,*, Jeffrey M. Halpern1,†,*, Qing-Ling Hua2, Yue-Yin Pan2, Haneen Kayal1, Kayan Khoury1, Hu Liu2, Michael P.A. Davies3, Hossam Haick1

1Department of Chemical Engineering and Russel Berrie Nanotechnology Institute, Technion-Israel Institute of Technology, Haifa, Israel

2Department of Oncology, the First Affiliated Hospital of Anhui Medical University, Anhui, China

3Molecular & Clinical Cancer Medicine, University of Liverpool, Cancer Research Centre, Liverpool, United Kingdom

Present Address: Department of Chemical Engineering, University of New Hampshire, Durham, NH, USA

*These authors have contributed equally to this work

Correspondence to:

Hossam Haick, e-mail: hhossam@technion.ac.il

Michael Davies, e-mail: michael.davies@liv.ac.uk

Hu Liu, e-mail: drliuhu@gmail.com

Keywords: breast cancer, molecular, volatolomic, sensor, spectrometry

Received: August 17, 2015     Accepted: October 10, 2015     Published: November 02, 2015

ABSTRACT

Mapping molecular sub-types in breast cancer (BC) tumours is a rapidly evolving area due to growing interest in, for example, targeted therapy and screening high-risk populations for early diagnosis. We report a new concept for profiling BC molecular sub-types based on volatile organic compounds (VOCs). For this purpose, breath samples were collected from 276 female volunteers, including healthy, benign conditions, ductal carcinoma in situ (DCIS) and malignant lesions. Breath samples were analysed by gas chromatography mass spectrometry (GC-MS) and artificially intelligent nanoarray technology. Applying the non-parametric Wilcoxon/Kruskal-Wallis test, GC-MS analysis found 23 compounds that were significantly different (p < 0.05) in breath samples of BC patients with different molecular sub-types. Discriminant function analysis (DFA) of the nanoarray identified unique volatolomic signatures between cancer and non-cancer cases (83% accuracy in blind testing), and for the different molecular sub-types with accuracies ranging from 82 to 87%, sensitivities of 81 to 88% and specificities of 76 to 96% in leave-one-out cross-validation. These results demonstrate the presence of detectable breath VOC patterns for accurately profiling molecular sub-types in BC, either through specific compound identification by GC-MS or by volatolomic signatures obtained through statistical analysis of the artificially intelligent nanoarray responses.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 6269